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Abstract
In Brazil, governmental and non-governmental organisations develop practice guidelines (PGs) in order to optimise
patient care. Although important improvements have been made over the past years, many of these documents
still lack transparency and methodological rigour. In order to conduct a critical analysis and define future steps in
PG development in Brazil, we carried out a structured assessment of strengths, weaknesses, opportunities and
threats (SWOT analysis) for the development of a national guideline programme. Participants consisted of academia,
methodologists, medical societies and healthcare system representatives. In summary, the PG development process
has improved in Brazil and current investments in methodological research and capacity-building are ongoing.
Despite the centralised processes for public PGs, standardised procedures for their development are not well
established and human resources are insufficient in number and capacity to develop the amount of trustworthy
documents needed. Brazil’s capacity could be strengthened and initial efforts have been made such as the
adoption of standards proposed by world-renowned institutions in PG development and enhancement of the
involvement of key stakeholders. Further steps involve the alignment between health technology assessment and
PG processes for synergy and the development of a national network to promote the interaction between groups
involved in the development of PGs. The lessons learned from this paper could be used to foster debate on
guideline development, especially for countries facing similar threats on this topic.
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Introduction
The public healthcare system for 209 million Brazilians
is based on the principles of universal access, compre-
hensive coverage, equity, decentralisation and social par-
ticipation [1]. In Brazil, 100% of the population have
access to healthcare through the Brazilian Unified Public
Healthcare System (Sistema Único de Saúde; SUS) and
approximately one-quarter of those have additional
private health insurance coverage or pay directly for ser-
vices received [2].
The Brazilian Ministry of Health (MoH) develops na-
tional practice guidelines (PGs) for health professionals
and policy-makers based on technologies that are used
across the SUS in order to establish standards for the
diagnosis and treatment in public healthcare settings.
New technologies are first subject to a systematic
assessment by the National Committee for Health Tech-
nology Incorporation (CONITEC) [3, 4]. This committee
is composed of stakeholders from different health-
related sectors of society (including members of the
MoH, members of health regulatory agencies and
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representatives of national health councils). The CONI-
TEC advises the MoH on policies regarding the incorp-
oration and removal of technologies, which include
decisions for the coverage of medicines, diagnostic tests,
products and procedures in the SUS. This process is
supported by health technology assessment (HTA), in-
cluding systematic reviews of the effects of technologies,
cost-effectiveness analysis and budget impact assess-
ment. If the CONITEC’s decision results in the coverage
of a new technology by the public health system, CONI-
TEC requests the update of Brazilian MoH guidelines in
order to allows its implementation [3–5]. Thus, PGs play
a crucial role in Brazilian healthcare delivery. Moreover,
they require integration with HTA, which presents a
unique opportunity for collaboration between key stake-
holders in the health system. This may be used as a
model for other countries wishing to both improve care
and save resources by increasing cost-effectiveness
through evidence assessment and implementation
processes.
The current guideline development process in Brazil
In Brazil, governmental and non-governmental organisa-
tions, such as professional societies and the MoH, de-
velop PGs. While PGs developed by the former
primarily aim to inform healthcare professionals about
best practices, MoH PGs also aim to standardise prac-
tices for the public health system. Different departments
in the MoH may produce documents with healthcare
recommendations, but PGs developed by CONITEC
have a normative role, defining the available technolo-
gies and circumstances for their implementation in the
SUS. These PGs are developed by academic and health-
care institutions, commissioned by the MoH, responsible
for evidence review and guideline panels. The PGs are
reviewed by CONITEC, ensuring that recommendations
are aligned with services currently provided by the pub-
lic health system, and CONITEC may request modifica-
tions or even a new HTA assessment if a new
technology is recommended.
However, in Brazil, many PGs lack transparency and
methodological rigour [6–9] and do not strictly follow
the standards recommended by the Institute of Medicine
and the Guidelines International Network (GIN) [10–13].
Moreover, PGs developed by health professional societies
often receive funding from the pharmaceutical industry,
creating potential conflicts of interest. Nevertheless, the
country is experiencing an increasing need for trustworthy
recommendations and is trying to improve the PG devel-
opment process by enhancing the required methodo-
logical rigour and transparency [14].
The Brazilian MoH develops PGs through its own
technical staff from different Secretariats as well as hir-
ing institutions, such as federal universities and hospital-
based HTA units, to develop them. It is responsible for
the approval of the delivered products after public con-
sultation. This public consultation includes making a
preliminary version of the guideline available online to
gather input from society.
Given the importance and potential influence of PGs
on healthcare delivery to the 150 million Brazilians who
receive care exclusively through the public healthcare
sector, there is a need to keep up with best practices in
guideline development and implementation and to de-
fine the next steps for Brazil. Concerned with the growth
and improvement of PG development methodology and
in an attempt to bring together professional societies
and the public healthcare sector, the authors of this
paper conducted a critical analysis and defined the ne-
cessary future actions by key players in Brazil. We used
a systematic approach (Fig. 1), the basis of which is pre-
sented in Additional file 1.
Strengths, weaknesses, opportunities and threats for
guideline development in Brazil
An important strength of PG development in Brazil is
that its healthcare system uses a centralised process for
guideline development and approval, which leads dir-
ectly to the implementation of PG recommendations in
the public sector. The Department of Management and
Incorporation of Health Technologies (DGITIS) of the
Brazilian MoH is responsible for managing and coordin-
ating activities related to the development of guidelines
for the public healthcare system. This process is
followed by a CONITEC assessment and public consult-
ation, and the document is finally approved by the re-
sponsible manager of the SUS and officially published.
As these PGs are official documents with guidance for
healthcare professionals and policy-makers, they shorten
the gap between the development and implementation
of recommendations in the public health system. Add-
itionally, the representative composition of the CONI-
TEC increases the legitimacy and transparency of the
recommendations, as does the public consultation
process.
The Department of Management and Incorporation of
Health Technologies and the CONITEC were only cre-
ated in 2011 and, although core activities are well estab-
lished and implemented, especially those related to
HTA, some of their processes are still in the early stages
of development and refinement. As in any newly formed
organisation that is linked to the government, constant
changes in policies and politics can negatively affect the
flow of activities. The process can be further jeopardised
if there is strong external pressure from stakeholders,
such as pharmaceutical industry, medical societies and
patient organisations, especially in the absence of well-
defined policies governing conflicts of interest. Thus, the
Colpani et al. Health Research Policy and Systems           (2020) 18:69 Page 2 of 6
Fig. 1 Key aspects of the current scenario and future directions to enhance PG development in Brazil. PG practice guideline, HTA health
technology assessment
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development of a sound conflict of interest policy may
minimise inequities, save resources, and reduce the like-
lihood of errors and biases in the process. For example,
some stakeholders, as medical societies, may adopt an
independent reviewer board for the approval process
and require disclosure of conflicts of interest prior to the
panel meeting as well as for publication along with the
guideline to maximise editorial independence. In
addition, as there is a need for long-term policies in the
field of guidelines, the presence of uncertainties of the
continuity of investments in PG development pro-
grammes is a major potential pitfall on achieving the de-
sired outcome, which includes investments in
methodological research and capacity-building.
Despite the centralised processes, the procedures for
PG development are not well established. Although
there are several guiding documents and experts avail-
able in the country, the methods used in the develop-
ment of PGs in Brazil need to be improved. The
professionals involved in the process should be following
international standards, such as those of GIN or the In-
stitute of Medicine, and use established approaches to
assessing evidence and develop trustworthy recommen-
dations. Additionally, more research should be carried
out to evaluate the quality of PGs in order to assess its
improvement over time [10, 11, 15]. For example,
developing guidelines is a complex process that requires
standardised methods and specific knowledge of epi-
demiology, public health, health economics, evidence-
based medicine, and group leadership and processes.
Currently, human resources are insufficient in number
and capacity to efficiently produce trustworthy guide-
lines on a larger scale. Because the PGs developed by the
Brazilian MoH define the technologies that will be cov-
ered by the public healthcare system, the lack of updated
guidelines results in an increase in litigation as a means
of achieving care. In the absence of updated recommen-
dations, patients may obtain the right to an intended
intervention through the legal system, a process which
circumvents formal evidence-based analysis, resulting in
higher costs and suboptimal use of resources. Currently,
the cost of litigation accounts for about US$ 3–4 billion
in expenses annually, corresponding to almost 10% of
the total MoH budget. Additionally, in Brazil, national
evidence is lacking for questions related to several
neglected diseases, patient and social values, and prefer-
ences, costs, equity and acceptability by patients and
policy-makers.
Some initial efforts have been made to improve guide-
line development and translation into health policies in
Brazil. The MoH has begun to standardise PG
methodology, following standards recommended by
world-renowned institutions such as WHO. Continuing
to integrate other well-established methods such as
GRADE will be key in the improvement of the Brazilian
PG process [10–12, 15–17].
In addition, governmental agencies have begun to in-
vest in training and methods development projects, in-
volving key stakeholders (e.g. national organisations,
academia, professional societies, healthcare providers,
policy-makers, patients and society), in order to improve
PG and HTA development. Additionally, the MoH now
promotes synergy between HTA and PG development.
Although PGs and HTA share important similarities
(such as evidence synthesis, a structured decision frame-
work and internal approval processes), they have been
developed independently of one another in Brazil. Des-
pite these signals of progress, there is still a long way to
go to ensure that the different stakeholders will work
efficiently together, particularly with respect to priority-
setting and sharing a common agenda for guideline de-
velopment and method standardisation. Achieving this
common agenda will avoid duplication of efforts.
A major current weakness that should be prioritised
for action is the language barrier. Documents in Brazil
are often published and disseminated in Portuguese,
which hinders international collaboration between
guideline development teams as well as the worldwide
dissemination and critique of Brazilian PGs. However,
Brazil must be able to recognise and explore opportun-
ities for partnerships with countries and international
organisations that apply proper PG development pro-
cesses, including guideline adaptation and external sup-
port, in order to reduce costs and increase work
efficiency. Collaborative regional initiatives may be an
option. For instance, Brazil is a member of the Health
Technology Assessment Network of the Americas and
The International Network of Agencies for HTA, both
of which generate opportunities for collaboration and
sharing of relevant knowledge with other organisations,
especially from low- and middle-income countries. Many
low- and middle-income countries face similar political
and economic challenges. Collaborations that have been
established in the field of HTA may be expanded to
guideline development, thus being one of the aims of the
GIN International Network of Agencies for HTA work-
ing group.
Considering PGs as an evidence synthesis and
evidence-based support tool, Brazil is only one of many
countries making efforts to change their development
process. Improvements have been made, such as the im-
plementation of a centralised process, the use of a stand-
ard methodology as GRADE and the investment in
training [18–21], but there still are further steps to be
taken. Given that one of our goals is to improve PG de-
velopment and dissemination, it is important as a first
step to prioritise topics that focus on the major needs of
the population. In the long term, this may reduce
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inequalities in the treatment of prevalent diseases. An-
other obstacle is that the guideline development process
still depends largely on a few groups of experts in guide-
line methodology. A lack of funding to stimulate the inter-
est and growth of competence in this field has limited its
spread to universities and research institutions, posing a
threat to the long-term sustainability of PG development
programmes. Furthermore, it is important that, after stan-
dardising the methods for PG development and dissemin-
ation, strategies for the effective implementation of PGs
are required. There are several options requiring a multi-
faceted approach to the development of user-friendly ma-
terial by all stakeholders and strategies for the application
of PG recommendations to clinical practice.
Conclusion
The PG development process has improved in Brazil but
the country still needs to adopt standard methods and
approaches to improve the trustworthiness of its PGs.
This analysis, summarised in Fig. 1, presents key aspects
of the current scenario and future directions to enhance
PG development in Brazil.
Fostering debate on PG development across the coun-
try is important to act in synergy with international
agencies and to develop better national guidelines fol-
lowing similar initiatives taking place in other advancing
countries such as China and India [22–24]. In this con-
text, international collaboration will help in capitalising
on the international experience to improve the PG
process. This, in turn, should promote the rational use
of resources in order to provide the best available tech-
nologies for the Brazilian population.
The authors of this article agreed on the main steps that
need to be taken to improve PGs in Brazil, including the
establishment of a national network for PG development
and the standardisation of methods using well-established
international methodologies. A collaborative network is
needed to avoid the duplication of efforts and align
methods and quality standards. This network should en-
hance the relationship between groups and institutions
engaged in PG and HTA development, both at national
and international level. This approach of incorporating
different groups in the process should promote the devel-
opment of an integrative environment and nurture a cul-
ture that stimulates the sharing of strategies for PG
development and use in Brazil.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12961-020-00582-0.
Additional file 1. Methods and approach for assessing the status of
guideline development in Brazil and defining future directions at the
national level.
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